SrasV1, PubMed, Curation, bibRecord, 002A06

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.

Identifieur interne : 002A06 ( PubMed/Curation ); précédent : 002A05; suivant : 002A07

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.

Auteurs : Di Qu [République populaire de Chine] ; Bojian Zheng ; Xin Yao ; Yi Guan ; Zheng-Hong Yuan ; Nan-Shan Zhong ; Li-Wei Lu ; Jian-Ping Xie ; Yu-Mei Wen

Source :

Vaccine [ 0264-410X ] ; 2005.

RBID : pubmed:15603894

Descripteurs français

KwdFr :
- Administration par voie nasale, Animaux, Anticorps antiviraux (biosynthèse), Anticorps antiviraux (sang), Cellules Vero, Femelle, Humains, Mâle, Poumon (immunologie), Poumon (métabolisme), Souris, Souris de lignée BALB C, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
MESH :
- administration et posologie : Vaccins antiviraux, Vaccins inactivés.
- biosynthèse : Anticorps antiviraux.
- immunologie : Poumon, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- métabolisme : Poumon.
- sang : Anticorps antiviraux.
- Administration par voie nasale, Animaux, Cellules Vero, Femelle, Humains, Mâle, Souris, Souris de lignée BALB C.

English descriptors

KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (biosynthesis), Antibodies, Viral (blood), Chlorocebus aethiops, Female, Humans, Lung (immunology), Lung (metabolism), Male, Mice, Mice, Inbred BALB C, SARS Virus (immunology), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology), Vero Cells, Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Vaccines, Inactivated, Viral Vaccines.
- chemical , biosynthesis : Antibodies, Viral.
- chemical , blood : Antibodies, Viral.
- immunology : Lung, SARS Virus, Vaccines, Inactivated, Viral Vaccines.
- metabolism : Lung.
- Administration, Intranasal, Animals, Chlorocebus aethiops, Female, Humans, Male, Mice, Mice, Inbred BALB C, Vero Cells.

Abstract

SARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID(5.0) of the live virus 10(3.6) to 10(4.6) times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed.

DOI: 10.1016/j.vaccine.2004.07.031
PubMed: 15603894

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A06

Links to Exploration step

pubmed:15603894

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.</title>
<author><name sortKey="Qu, Di" sort="Qu, Di" uniqKey="Qu D" first="Di" last="Qu">Di Qu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology/Ministry of Education, Ministry of Public Health, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology/Ministry of Education, Ministry of Public Health, Shanghai Medical College, Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Bojian" sort="Zheng, Bojian" uniqKey="Zheng B" first="Bojian" last="Zheng">Bojian Zheng</name>
</author>
<author><name sortKey="Yao, Xin" sort="Yao, Xin" uniqKey="Yao X" first="Xin" last="Yao">Xin Yao</name>
</author>
<author><name sortKey="Guan, Yi" sort="Guan, Yi" uniqKey="Guan Y" first="Yi" last="Guan">Yi Guan</name>
</author>
<author><name sortKey="Yuan, Zheng Hong" sort="Yuan, Zheng Hong" uniqKey="Yuan Z" first="Zheng-Hong" last="Yuan">Zheng-Hong Yuan</name>
</author>
<author><name sortKey="Zhong, Nan Shan" sort="Zhong, Nan Shan" uniqKey="Zhong N" first="Nan-Shan" last="Zhong">Nan-Shan Zhong</name>
</author>
<author><name sortKey="Lu, Li Wei" sort="Lu, Li Wei" uniqKey="Lu L" first="Li-Wei" last="Lu">Li-Wei Lu</name>
</author>
<author><name sortKey="Xie, Jian Ping" sort="Xie, Jian Ping" uniqKey="Xie J" first="Jian-Ping" last="Xie">Jian-Ping Xie</name>
</author>
<author><name sortKey="Wen, Yu Mei" sort="Wen, Yu Mei" uniqKey="Wen Y" first="Yu-Mei" last="Wen">Yu-Mei Wen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15603894</idno>
<idno type="pmid">15603894</idno>
<idno type="doi">10.1016/j.vaccine.2004.07.031</idno>
<idno type="wicri:Area/PubMed/Corpus">002A06</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A06</idno>
<idno type="wicri:Area/PubMed/Curation">002A06</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A06</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.</title>
<author><name sortKey="Qu, Di" sort="Qu, Di" uniqKey="Qu D" first="Di" last="Qu">Di Qu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology/Ministry of Education, Ministry of Public Health, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology/Ministry of Education, Ministry of Public Health, Shanghai Medical College, Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Bojian" sort="Zheng, Bojian" uniqKey="Zheng B" first="Bojian" last="Zheng">Bojian Zheng</name>
</author>
<author><name sortKey="Yao, Xin" sort="Yao, Xin" uniqKey="Yao X" first="Xin" last="Yao">Xin Yao</name>
</author>
<author><name sortKey="Guan, Yi" sort="Guan, Yi" uniqKey="Guan Y" first="Yi" last="Guan">Yi Guan</name>
</author>
<author><name sortKey="Yuan, Zheng Hong" sort="Yuan, Zheng Hong" uniqKey="Yuan Z" first="Zheng-Hong" last="Yuan">Zheng-Hong Yuan</name>
</author>
<author><name sortKey="Zhong, Nan Shan" sort="Zhong, Nan Shan" uniqKey="Zhong N" first="Nan-Shan" last="Zhong">Nan-Shan Zhong</name>
</author>
<author><name sortKey="Lu, Li Wei" sort="Lu, Li Wei" uniqKey="Lu L" first="Li-Wei" last="Lu">Li-Wei Lu</name>
</author>
<author><name sortKey="Xie, Jian Ping" sort="Xie, Jian Ping" uniqKey="Xie J" first="Jian-Ping" last="Xie">Jian-Ping Xie</name>
</author>
<author><name sortKey="Wen, Yu Mei" sort="Wen, Yu Mei" uniqKey="Wen Y" first="Yu-Mei" last="Wen">Yu-Mei Wen</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibodies, Viral (biosynthesis)</term>
<term>Antibodies, Viral (blood)</term>
<term>Chlorocebus aethiops</term>
<term>Female</term>
<term>Humans</term>
<term>Lung (immunology)</term>
<term>Lung (metabolism)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>SARS Virus (immunology)</term>
<term>Vaccines, Inactivated (administration & dosage)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Vero Cells</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Anticorps antiviraux (biosynthèse)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Cellules Vero</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Poumon (immunologie)</term>
<term>Poumon (métabolisme)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins inactivés (administration et posologie)</term>
<term>Vaccins inactivés (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Poumon</term>
<term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term>
<term>SARS Virus</term>
<term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Cellules Vero</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">SARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID(5.0) of the live virus 10(3.6) to 10(4.6) times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15603894</PMID>
<DateCompleted><Year>2005</Year>
<Month>03</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>23</Volume>
<Issue>7</Issue>
<PubDate><Year>2005</Year>
<Month>Jan</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.</ArticleTitle>
<Pagination><MedlinePgn>924-31</MedlinePgn>
</Pagination>
<Abstract><AbstractText>SARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID(5.0) of the live virus 10(3.6) to 10(4.6) times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qu</LastName>
<ForeName>Di</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology/Ministry of Education, Ministry of Public Health, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Bojian</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yao</LastName>
<ForeName>Xin</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guan</LastName>
<ForeName>Yi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yuan</LastName>
<ForeName>Zheng-Hong</ForeName>
<Initials>ZH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhong</LastName>
<ForeName>Nan-Shan</ForeName>
<Initials>NS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Li-Wei</ForeName>
<Initials>LW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xie</LastName>
<ForeName>Jian-Ping</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wen</LastName>
<ForeName>Yu-Mei</ForeName>
<Initials>YM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>07</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>3</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId>
<ArticleId IdType="pii">S0264-410X(04)00583-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2004.07.031</ArticleId>
<ArticleId IdType="pmc">PMC7115388</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viral Immunol. 1998;11(4):245-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10189191</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 1998 Nov 1;161(9):4463-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9794366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1998 Oct;72(10):8220-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9733865</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 May 13;94(10):5267-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9144226</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2002 Jul;76(13):6568-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12050369</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biotechnol Prog. 1996 May-Jun;12(3):406-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8652125</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Immun. 2001 Aug;69(8):4870-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11447162</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunology. 2003 Nov;110(3):341-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14632662</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1773-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781536</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pharmacol Exp Ther. 2001 Jun;297(3):1059-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11356929</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 1997 Feb;175(2):292-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9203649</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 1996 Dec;46(1-2):111-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9029784</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1999 Sep;73(9):7565-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10438846</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Immun. 2001 Jul;69(7):4545-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11401998</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Mar;77(6):3615-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12610137</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A06 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002A06 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15603894
   |texte=   Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15603894" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki